EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the…
WILMINGTON, Del., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced a…
NEW YORK and LONDON and BERLIN and TOKYO, Feb. 4, 2025 /PRNewswire/ -- Sony Group Corporation (Sony) and Nature are proud…
CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated…
CHATHAM, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated…
Provides 23andMe+ Premium members with insight into their likelihood of developing osteoporosis based on thousands of genetic variantsSUNNYVALE, Calif., Jan.…
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”)…